PitchSend

Investor Presentaiton

Commercialisation: Vanderbilt PDRS trial results PDRS is not detectable by Spirometry, X-ray or CT only via surgical biopsy. XV clinical trial outputs displaying ventilation variation • 4DMedical's XV Technology® detects the presence of constrictive bronchiolitis. Quantitative scores identify the differences between Veterans with constrictive bronchiolitis and healthy controls. XV TechnologyⓇ confirmed the diagnosis of CB with <0.001% uncertainty. Ongoing assessment of the Vanderbilt clinical trial data is expected to lead to publication. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 HEALTHY DISEASE 4DMedical™ XV Technology® confirmed the diagnosis of CB with <0.001% uncertainty. 22 222

View entire presentation